Nasdaq:US$14.72 (-0.05) | HKEX:HK$23.24 (+0.00) | AIM:£2.17 (-0.01)
Search
News & Press Releases
1234567
8
9
found Documents: 447
Announcements & Press Releases, Group | 16 Oct 2015

Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
The following includes the text of the Announcement but excludes the appendix. For the complete release, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 13 Oct 2015

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma
Press Release London: Tuesday, 13 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, and AstraZeneca AB (publ) (“AstraZeneca”) ha
Read More
View PDF
Announcements & Press Releases, Group | 8 Oct 2015

Winner of International Company of the Year 2015, AIM
At the 2015 AIM Awards, Chi-Med was awarded the title of International Company of the Year. The AIM Awards look at how companies and individuals harness AIM to power their growth and fulfil their strategy. The AIM Awards scrutinises recent joiners
Read More
Announcements & Press Releases, Oncology / Immunology | 14 Sep 2015

Fruquintinib Phase II clinical results in colorectal cancer to be presented at the 2015 European Cancer Congress
London: Monday, 14 September 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present the detailed clinical results of its Phase II proo
Read More
View PDF
Announcements & Press Releases, Oncology / Immunology | 2 Sep 2015

Second proof-of-concept trial of fruquintinib achieves its primary endpoint
London: Wednesday, 2 September 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proo
Read More
View PDF
Announcements & Press Releases, Oncology / Immunology | 19 Aug 2015

Termination of Research & Development Alliance Agreement with Janssen Relating to HMPL-507 Project
London: Wednesday, 19 August 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that, Hutchison MediPharma Limited (“HMP”), its R&D subsidiary, has received notice from Janssen Pharmaceutical, Inc. (Janssen) of
Read More
View PDF
Announcements & Press Releases, Group | 28 Jul 2015

Interim Results for the Six Months Ended 30 June 2015
For the complete release, please download the PDF. --- Drug R&D Division - our Innovation Platform: enrolling 17 clinical trials (H1 2014: 10), with 24 targeted by year-end. China Healthcare and Consumer Products Divisions - our Commercial
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 Jul 2015

Mitsui exchanges its shares in Hutchison MediPharma for shares in Chi-Med
London: Thursday, 23 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that it has signed a subscription agreement (the "Agreement") and completed the exchange of 5,247,493 convertible preference shares held by Mitsui
Read More
PDF
Announcements & Press Releases, Other Ventures | 17 Jul 2015

20-year invention patent granted on Chi-Med's best selling prescription drug
London: Friday, 17 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its prescription drug joint venture, has been granted an invention patent in China ("Inven
Read More
a150717
Announcements & Press Releases, Oncology / Immunology | 1 Jun 2015

Savolitinib (AZD6094) preliminary Phase Ib clinical data in lung cancer presented at the 2015 ASCO Annual Meeting
London: Monday, 1 June 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM), today announces that AstraZeneca AB (publ) (“AstraZeneca”), Hutchison MediPharma Limited’s (“HMP”) collaboration partner, presented preliminary data f
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 13 May 2015

Positive fruquintinib proof-of-concept study results trigger payments from Lilly
London: Wednesday, 13 May 2015: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned drug R&D company, is set to receive a total of US$18 million in payments, in the second quarter of 2015, from Eli Lilly and
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 30 Mar 2015

The first proof-of-concept trial of fruquintinib achieves primary efficacy endpoint
London: Monday, 30 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, successfully achieved the primary endpoint in the first proof-of-concept ("POC") trial of fruquintinib in pati
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Mar 2015

Patient enrolment completion for fruquintinib's Phase II study in non-small cell lung cancer; Fruquintinib development moving rapidly in four parallel studies in non-small cell lung cancer, colorectal cancer and gastric cancer
London: Friday, 6 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in non-small cell lung
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 26 Feb 2015

Final Results for the year ended 31 December 2014
For the complete release, please download the PDF. -- Break-out year for Drug R&D Division with 16 clinical studies on 7 drug candidates; 10 potential Breakthrough Therapy indications; as well as record China Healthcare Division revenues and
Read More
View Announcement (PDF)
Announcements & Press Releases, Other Ventures, Press Releases | 29 Jan 2015

Hutchison Sinopharm and AstraZeneca China signed an exclusive distribution agreement on Seroquel® in China
Press Release -  London: Thursday, 29 January 2015: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"),
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 15 Dec 2014

Initiation of fruquintinib Phase III registration study in colorectal cancer
London: Monday, 15 December 2014: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, has initiated FRESCO, a Phase III registration study in colorectal cancer (“CRC”) patients in China, for
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 7 Oct 2014

Drug R&D Update Briefing for Analysts and Investors on 17 October 2014
Press Release -  London: Tuesday, 7 October 2014:  Chi-Med today announces that it will host a briefing to update analysts and investors on Hutchison MediPharma Limited (“HMP”), its majority owned pharmaceutical R&D division, in London o
Read More
View Announcement (PDF)
Announcements & Press Releases, Other Ventures, Press Releases | 1 Oct 2014

Chi-Med and Merck Serono sign co-promotion agreement
Press Release -  London: Wednesday, 1 October 2014: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Chi-Med, through its subsidiary Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company L
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 21 Aug 2014

Patient enrolment completed ahead of schedule for fruquintinib's Phase II study in colorectal cancer
London: Thursday, 21 August 2014: Chi-Med, today announces that Hutchison MediPharma Limited (“HMP”), its majority owned drug R&D company, has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in colorectal c
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 13 Aug 2014

HMPL-004 NATRUL-3 interim analysis result
London: Wednesday, 13 August 2014: Nutrition Science Partners Limited (“NSP”), a 50/50 joint venture between Chi-Med and Nestlé Health Science SA, today announces that a planned interim analysis was conducted on NATRUL-3, the global Phase III in
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 29 Jul 2014

Interim Results for the Six Months Ended 30 June 2014
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 18 Jun 2014

Initiation of Phase I clinical trial of novel Syk Inhibitor HMPL - 523 for autoimmune diseases
London: Wednesday, 18 June 2014: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), the majority owned R&D company of Chi-Med, has initiated the first-in-human Phase I clinical trial of HMPL-523 in Australia.  HMPL-523 is a n
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 5 Jun 2014

Initiation of fruquintinib Phase II study in non-small cell lung cancer
London: Thursday, 5 June 2014: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, has initiated a Phase II clinical trial in non-small cell lung cancer (“NSCLC”) patients in China for fruqui
Read More
View Announcement (PDF)
Announcements & Press Releases, Other Ventures | 30 May 2014

Chi-Med and Shanghai Traditional Chinese Medicine expand commercial cooperation
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 May 2014

Initiation of AZD6094 (HMPL-504/volitinib) Global Phase II Study in Papillary Renal Cell Carcinoma
London: Friday, 23 May 2014: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), Chi- Med’s majority owned R&D company, and AstraZeneca AB (publ) (“AstraZeneca”) have initiated a global Phase II study to evaluate the effi
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 22 May 2014

Phase I clinical data for selective VEGFR, c-Met and VEGFR/FGFR inhibitors to be presented at the 2014 ASCO Annual Meeting
London: Thursday, 22 May 2014: Chi-Med today announces that data from recent Phase I and Phase Ib clinical studies by Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, will be presented at the 50th Annual Meeting of the Am
Read More
View Announcement (PDF)
Announcements & Press Releases, Other Ventures | 17 Apr 2014

Chi-Med and Sinopharm complete regulatory approval for the establishment of new China drug distribution and marketing Joint Venture
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 4 Apr 2014

Presentations of volitinib and epitinib data at the 2014 AACR Annual Meeting
London: Friday, 4 April 2014: Chi-Med today announces that data from certain preclinical and clinical studies by Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, will be presented at the 105th Annual Meeting of the Americ
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 4 Apr 2014

Initiation of fruquintinib Phase II study in colorectal cancer
London: Friday, 4 April 2014: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, has initiated a Phase II clinical trial in colorectal cancer (“CRC”) patients in China for fruquintinib (HMPL
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 18 Feb 2014

Final Results for the year ended 31 December 2013
View Announcement (PDF)
Announcements & Press Releases, Other Ventures | 18 Dec 2013

Chi-Med and Sinopharm form China drug distribution and marketing joint venture
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 9 Oct 2013

Chi-Med's Pharmaceutical R&D Business - Analyst & Investor Briefing
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 9 Oct 2013

Candidate Nomination of Novel Small-Molecule Therapy in Inflammation Triggers Milestone Payment From Janssen Pharmaceuticals, Inc.
London: Wednesday, 9 October 2013: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, is set to receive a milestone payment of US$6 million from Janssen Pharmaceuticals, Inc. (“Janssen”), pu
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 9 Oct 2013

Cancer Therapy Collaboration with Lilly
London: Wednesday, 9 October 2013: Hutchison MediPharma Limited ("HMP"), an R&D company majority owned by Chi-Med, today announces that it has entered into a licensing, co-development, and commercialisation agreement in China with Eli Lilly and C
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 3 Oct 2013

Analyst briefing on Chi-Med's pharmaceutical R&D business on 9 October 2013
View Announcement (PDF)
Announcements & Press Releases, Group | 30 Jul 2013

Interim Results for the Six Months Ended 30 June 2013
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 17 Jul 2013

Nutrition Science Partners announces initiation of NATRUL-4, the maintenance study of the global Phase III trial for HMPL-004
London: Wednesday, 17 July 2013: Nutrition Science Partners, a 50/50 joint venture between Chi-Med and Nestlé Health Science, today announces that the first patient has begun treatment in the second global Phase III study of HMPL-004, NATRUL-4, for
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 25 Jun 2013

Initiation of Volitinib China Phase I study triggers US$5 million milestone payment
Australia Phase I study to report in late 2013 London: Tuesday, 25 June 2013:  Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, has initiated the Phase I clinical trial of Volitinib (HMPL-50
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 24 Apr 2013

Nutrition Science Partners announces initiation and treatment of the first Ulcerative Colitis patient in the global NATRUL Phase III trial for the novel botanical oral drug HMPL-004
London: Wednesday, 24 April 2013: Nutrition Science Partners, a 50/50 joint venture between Chi-Med and Nestlé Health Science, today announces that the first patient has been enrolled and has begun treatment in the first global Phase III study of HM
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 12 Apr 2013

Nestlé Health Science and Chi-Med complete regulatory approvals for the establishment of Nutrition Science Partners Joint Venture
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Apr 2013

Presentations of Fruquintinib Phase I Clinical Data and Volitinib Preclinical Data at the 2013 AACR Annual Meeting
London: Monday, 8 April 2013: Chi-Med today announces that data from the recently completed Phase I clinical trial of Fruquintinib (HMPL-013) and from preclinical studies of Volitinib (HMPL-504), two of the novel small molecule targeted anti-cancer d
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 26 Mar 2013

Final Results for the year ended 31 December 2012
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 28 Nov 2012

Chi-Med and Nestlé Health Science establish Joint Venture
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 1 Nov 2012

Hutchison MediPharma Limited initiates Phase I clinical study with its novel EGFR inhibitor Theliatinib
London: Wednesday, 31 October 2012: Chi-Med announced that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, initiated the first-in-human Phase I clinical trial of Theliatinib (HMPL-309).  This is the fourth oncology comp
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 31 Jul 2012

Interim Results for the Six Months Ended 30 June 2012
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Jun 2012

Hutchison MediPharma Limited Announces Presentations of Sulfatinib and Fruquintinib Clinical Data at the 2012 ASCO Annual Meeting
View Announcement (PDF)
Announcements & Press Releases, Group | 20 Mar 2012

Final Results for the year ended 31 December 2011. Strong growth. Positive outlook
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 22 Feb 2012

Hutchison MediPharma Limited initiates Phase I clinical study of its novel c-Met inhibitor Volitinib
London: Wednesday, 22 February 2012: Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announces the initiation of the first-in-human Phase I clinical trial of Volitinib (HMPL-504) in Australia.  Volitinib
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 21 Dec 2011

AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy
London: Wednesday, 21 December 2011: AstraZeneca and Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announce that they have entered into a global licensing, co-development, and commercialisation agreemen
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 4 Nov 2011

Hutchison MediPharma Limited initiates Phase I clinical study for its novel EGFR inhibitor Epitinib
London, Friday, 4 November 2011: Hutchison MediPharma Limited (“HMP”), the drug R&D company majority owned by Chi-Med, today announces the initiation of the first-in-human Phase I clinical trial of Epitinib (HMPL-813).  This is the third onc
Read More
a111104
1234567
8
9